Product Images Doxorubicin Hydrochloride

The text describes a figure, namely a meta-analysis of disease-free survival. The hazard ratio of several trials is presented along with their confidence intervals. The trials included are NSABP B-15, SEOSA 2, ONCOFRANCE, SE Sweden BCG A, NSABC Israel Bro283, Austrian BCSG 3. The figure also includes a comparison of Doxo based approaches (6 studies) with DOXO performing better than CMF in some cases and worse than CMF in others. Finally, a boundary of non-inferiority with CMF is mentioned as retaining 75% of CMF effect.*

The text is providing a figure labeled as "Figure 2" that includes a meta-analysis of overall survival from several clinical trials. The figure displays a Hazard Ratio for each trial, along with their corresponding 95% confidence intervals. The text also suggests that the analysis is focused on comparing two treatment options, DOXO (presumably a treatment containing Doxorubicin) and CMF. The results of the analysis are displayed on a scale ranging from 0 to 20 and suggest that DOXO is either better or worse than CMF, depending on the study. No further information is available to provide a more detailed description.*

This is a pharmaceutical product with NDC number 0143-9084-01. It contains DOXOrubicin which is mixed with FUDICIN and Sodium Chlorides. The product comes in a 5 mL single-dose vial which contains 10 mg of the mixture. It is meant for injection, and its storage temperature should be between 2°C to 8°C. The solution pH is adjusted to 3 using Hydrochloric Acid, and the product is preservative-free. The manufacturing company is Hikma and is distributed from Berkeley Heights, NJ 07522. There is a warning about severe cellulitis when the product is used, and it is for intravenous use ONLY.*

This is a description of NDG 0143-9085-01 R, a medication for intravenous use only. One mL of this medication contains 2 mg of Doxorubicin HCI, USP along with doxorubicin sodium chloride 0.9% and water. It is advised to store the medication in the refrigerator between 2° and 8°C (36° to 46°F). The medication is available in 10 mL single dose vials and is distributed by Hikma. The packaging warns about severe cellulitis, vesication, and tissue necrosis that may occur if the medication leaks into surrounding tissue during administration.*

This is a description of a prescription-only medication contained in a 25 mL single dose vial. The medication is Doxorubicin HCI used for intravenous administration. The package insert contains complete prescribing information. The medication should be stored in a refrigerator between 2°C and 8°C and protected from light, and any unused portion should be discarded. Severe cellulitis, vesication and tissue necrosis can occur if the medication is extravasated during administration. The medication is distributed by Hikma and manufactured by Thymoorgan Pharmazie GbH in Germany.*

This is a medication called DOXOrubicin HCI Injection, USP. It comes in a 100 mL Multiple Dose Vial with each mL containing 2 mg Doxorubicin HCI, USP. This medication is for intravenous use only, and is preservative-free and sterile. The usual dosage is included in the package inserts. The medication should be stored in a refrigerator between 2° to 8°C and protected from light. The medication is manufactured by THYMOORGAN PHARMAZIE GmbH, Germany and distributed by Hikma. The warning indicates that the medication can cause severe cellulitis vesication and tissue necrosis if extravasated during administration.*

This text contains product identification information such as GTIN (Global Trade Item Number), SN (Serial Number), EXP (Expiration Date), and LOT (Batch or Lot Number) that can be used to track and manage inventory and ensure product quality.*

The text contains a lot number "T Lot" and a product identifier "GTIN" along with its value "00301234567896". It also includes a serial number "SN" and its corresponding value "12345678901234". There's an expiration date recorded in the format of "MMMYYYY". This text might be part of a product label or packaging.*